A topic in the Open Knowledge Graph — a free, open map of 15,290 topics and the order to learn them in.
Developmental screening is the systematic use of standardized tools to identify children who may have developmental delays or disorders and who warrant further evaluation — it is not diagnostic but a population-level triage. The American Academy of Pediatrics recommends universal developmental surveillance at every well-child visit and standardized screening at 9, 18, and 30 months, with autism-specific screening at 18 and 24 months using tools like the Ages and Stages Questionnaire (ASQ) and the M-CHAT-R. Screening operates within a tiered model: surveillance (ongoing monitoring by providers), screening (standardized brief tools), comprehensive evaluation (multidisciplinary diagnostic assessment), and intervention. Accurate screening requires attention to cultural and linguistic factors that can produce false positives or negatives in standardized instruments.
Administer and score a standardized screening tool (e.g., ASQ) across hypothetical case vignettes representing typical, at-risk, and delayed profiles. Examine the sensitivity/specificity tradeoffs in screening tool selection and their implications for over- and under-identification.
Your study of Piaget's stages, infant motor development, and language acquisition gave you a map of what children typically do and when. Developmental screening is the population-level system for detecting when a child is significantly off that map — early enough that intervention can still reshape the trajectory. The critical insight is that screening sits between informal observation and diagnosis: it is systematic, standardized, and brief, but it is not sufficient to confirm a disorder. It answers the question "does this child warrant a closer look?" not "what is wrong with this child?"
The tiered model organizes clinical response by intensity. Developmental surveillance is ongoing — at every well-child visit, the pediatrician asks about milestones, observes the child, and notes parental concerns. This informal monitoring is sensitive to emerging patterns over time but has low specificity. When surveillance raises concern, or at the scheduled universal screening ages (9, 18, and 30 months), a standardized screening tool is administered. The Ages and Stages Questionnaire (ASQ) is a parent-completed tool that covers five domains: communication, gross motor, fine motor, problem-solving, and personal-social. Each domain has an empirically derived cutoff; scores below cutoff trigger referral. Importantly, the ASQ does not ask "does your child have autism" — it asks observable behavioral questions that parents can answer reliably, which is precisely what makes it scalable. When screening is positive, the next step is comprehensive evaluation by a multidisciplinary team (psychologist, speech-language pathologist, occupational therapist), which produces diagnosis and eligibility for services.
Autism-specific screening at 18 and 24 months adds another layer. The M-CHAT-R (Modified Checklist for Autism in Toddlers, Revised) focuses on early social-communication behaviors that are often the first detectable signs: does the child point to share interest (not just to request), respond to their name, engage in joint attention, and imitate? These behaviors emerge earlier than full language, which is why 18-month screening catches many children who would otherwise not raise concern until a speech delay became obvious at age 3. The research basis for early identification is that brain plasticity is highest in the first three years — early intensive intervention during this window produces outcomes significantly better than intervention that begins after age 5.
Sensitivity and specificity shape every screening tool decision. A highly sensitive tool (like M-CHAT-R without follow-up interview) catches almost all children with autism but also flags many who develop typically — high false-positive rate. Adding a brief structured follow-up interview dramatically improves specificity without sacrificing much sensitivity. Clinicians choose tools based on the tradeoff their context requires: a community health program with limited evaluation resources may favor higher specificity to avoid overwhelming the referral pipeline; a research study seeking complete case ascertainment may favor higher sensitivity. These are the same sensitivity-specificity tradeoffs from your epidemiology prerequisites, applied to a clinical population-screening context.
Cultural and linguistic validity is not a secondary concern — it is central to accurate screening. Standardized tools are normed on specific populations; when applied across linguistic, cultural, or socioeconomic boundaries without validation, the norms may not hold. A child raised in a bilingual household may be acquiring vocabulary more slowly in each language while total vocabulary is normal; a child from a culture with different expectations about infant-directed play may score below cutoff on items that assume Western middle-class parenting styles. Providers must interpret screening results in context, supplementing with clinical observation and parental report, and should actively seek culturally adapted tools when they exist.